Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Danila Branca"'
Autor:
Douglas G. Johns, Louis-Charles Campeau, Puja Banka, An Bautmans, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Paul G. Bulger, Inne Crevecoeur, Fa-Xiang Ding, Robert M. Garbaccio, Erik D. Guetschow, Yan Guo, Sookhee N. Ha, Jennifer M. Johnston, Hubert Josien, Eunkyung A. Kauh, Kenneth A. Koeplinger, Jeffrey T. Kuethe, Eseng Lai, Christine L. Lanning, Anita Y.H. Lee, Li Li, Anilkumar G. Nair, Edward A. O’Neill, S. Aubrey Stoch, David A. Thaisrivongs, Thomas J. Tucker, Petr Vachal, Kristien van Dyck, Frederic P. Vanhoutte, Bram Volckaert, Dennis G. Wolford, Andy Xu, Tian Zhao, Dan Zhou, Susan Zhou, Xiaohong Zhu, Hratch J. Zokian, Abbas Walji, Harold B. Wood
Publikováno v:
Circulation.
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite
Autor:
Thomas J. Tucker, Nianyu Li, Scott P. Salowe, Harold B. Wood, Danila Branca, Alan S. Bass, Rupesh P. Amin, BethAnn Murphy, Aurash Shahripour, Angela Kerekes, Abbas Walji, Nicole Buist, Jeffrey T. Kuethe, Huaibing He, Rodger Tracy, Kenneth A. Koeplinger, Weixun Wang, Bhavana Bhatt, Candice Alleyne, Sookhee Ha, Douglas G. Johns, Elisabetta Bianchi, Chengwei Wu, Peter Orth, Tjerk Bueters, Yusheng Xiong, Hratch J. Zokian, Michael J. Hafey, Mark W. Embrey, John Higgins
Publikováno v:
Journal of Medicinal Chemistry. 64:16770-16800
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. Starting from second-generation l
Autor:
Jesus Maria Ontoria Ontoria, Gabriella Dessole, Massimiliano Fonsi, Michael Rowley, Claudio Giuliano, Edith Monteagudo, Christian Steinkühler, Ester Muraglia, Caterina Torrisi, Maria Cecilia Palumbi, Danila Branca, Philip Jones, Laura Llauger Bufi, Alberto Bresciani
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:5283-5288
Smoothened (Smo) antagonists are emerging as new therapies for the treatment of neoplasias with aberrantly reactivated hedgehog (Hh) signaling pathway. A novel series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as smoothened antago
Autor:
Federica Orvieto, Danila Branca, Maria Cecilia Palumbi, Philip Jones, Ester Muraglia, Mauro Cerretani, Michael Rowley, Uwe Koch, Carlo Toniatti
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:4042-4045
PARP inhibitors have been demonstrated to retard intracellular DNA repair and therefore sensitize tumor cells to cytotoxic agents or ionizing radiation. We report the identification of a novel class of PARP1 inhibitors, containing a pyrrolo moiety fu
Autor:
Samuele Lillini, Carsten Schultz-Fademrecht, Edith Monteagudo, Carlo Toniatti, Ester Muraglia, Olaf Kinzel, Caterina Torrisi, Danila Branca, Laura Llauger Bufi, Federica Ferrigno, Michael Rowley, Philip Jones
Publikováno v:
Bioorganicmedicinal chemistry letters. 20(3)
We describe an extensive SAR study in the 6-[4-fluoro-3-(substituted)benzyl]-4,5-dimethylpyridazin-3(2H)-one series which led to the identification of potent PARP-1 inhibitors, capable of inhibiting the proliferation of BRCA-1 deficient cancer cells
Autor:
Carlo Toniatti, Fabrizio Fiore, Philip Jones, Laura Llauger Bufi, Danila Branca, Olaf Kinzel, Michael Rowley, Giovanna Pescatore, Caterina Torrisi, Ester Muraglia, Federica Orvieto
Publikováno v:
Bioorganicmedicinal chemistry letters. 20(3)
Herein we describe the discovery of a novel series of pyrrolo[1,2-a]pyrazin-1(2H)-one PARP inhibitors. Optimization led to compounds that display excellent PARP-1 enzyme potency and inhibit the proliferation of BRCA deficient cells in the low double-
Autor:
Maria Cecilia Palumbi, Olaf Kinzel, Sergio Serafini, Christian Steinkühler, Michael Rowley, Danila Branca, Gabriella Dessole, Philip Jones, Ester Muraglia, Federica Ferrigno
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(15)
We report the synthesis and biological evaluation of N-[(1-aryl-1H-indazol-5-yl)methyl]amide derivatives as Smoothened antagonists and inhibitors of the Hedgehog pathway. Identification of the lead structure 1 by HTS, followed by SAR study on the ami
Autor:
Philip Jones, Maria Cecilia Palumbi, Michael Rowley, Danila Branca, Claudia Giomini, Uwe Koch, Federica Orvieto, Carlo Toniatti, Jesus Maria Ontoria Ontoria, Ester Muraglia
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(15)
A novel series of pyrazolo[1,5-a]quinazolin-5(4H)-one derivatives proved to be a potent class of PARP-1 inhibitors. An extensive SAR around the 3-position of pyrazole in the scaffold led to the discovery of amides derivatives as low nanomolar PARP-1
Autor:
Christian Steinkühler, Maria Vittoria Orsale, Michael Rowley, Sergio Altamura, Philip Jones, Danila Branca, Ester Muraglia, Ottavia Cecchetti, Maria Cecilia Palumbi, Rita Scarpelli, Federica Ferrigno
Publikováno v:
Bioorganicmedicinal chemistry letters. 18(23)
Trifluoroacetylthiophene carboxamides have recently been reported to be class II HDAC inhibitors, with moderate selectivity. Exploration of replacements for the carboxamide with bioisosteric pentatomic heteroaromatic like 1,3,4-oxadiazoles, 1,2,4-oxa
Autor:
Johns, Douglas G., Campeau, Louis-Charles, Banka, Puja, Bautmans, An, Bueters, Tjerk, Bianchi, Elisabetta, Branca, Danila, Bulger, Paul G., Crevecoeur, Inne, Ding, Fa-Xiang, Garbaccio, Robert M., Guetschow, Erik D., Guo, Yan, Ha, Sookhee N., Johnston, Jennifer M., Josien, Hubert, Kauh, Eunkyung A., Koeplinger, Kenneth A., Kuethe, Jeffrey T., Lai, Eseng
Publikováno v:
Circulation; 7/11/2023, Vol. 148 Issue 2, p144-158, 15p